Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2025-02-12 08:00:00
Oslo, Norway, February 12th, 2025 - Lytix Biopharma today announces that the
United States Patent and Trademark Office (USPTO) has issued a Notice of
Allowance for U.S. Patent Application No. 18/598,719 with the title "Immune
Checkpoint Inhibitor Combinations".
This U.S. Patent will not only fortify Lytix Biopharma's intellectual property
portfolio by protecting the use of LTX-315 in conjunction with PD-1 immune
checkpoint inhibitor but also enhances our competitive edge in the burgeoning
U.S. pharmaceutical market. The patent will extend the effective patent life of
LTX-315, enabling us to secure our market position in the U.S. and maximize the
value of our clinical programs. Patent with similar protection have been granted
previously in other jurisdictions, thereby positioning Lytix at the forefront of
cancer immunotherapy development.
LTX-315 is currently being evaluated in two ongoing Phase II clinical trials in
combination with anti-PD-1 antibodies:
o ATLAS-IT-05 - Investigating LTX-315 in combination with pembrolizumab in
late-stage metastatic melanoma patients who have failed prior anti-PD-1/PD-L1
treatment.
o NeoLIPA - A neoadjuvant trial at Oslo University Hospital assessing LTX-315
with pembrolizumab in patients with earlier-stage, resectable melanoma.
"We are pleased to have received this Notice of Allowance in the United States,
reinforcing our competitive position in the world's largest pharmaceutical
market," said Baldur Sveinbjørnsson, CSO of Lytix Biopharma. "This patent will
further strengthen our business case as securing global intellectual property
rights is of critical importance for our technology platform and the long-term
value generation of the company."
For any questions, please contact:
Gjest Breistein, CFO
gjest.breistein@lytixbiopharma.com
+47 952 60 512
About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.